Journal of Enzyme Inhibition and Medicinal Chemistry · 2019 · 20 citations · 12 references
PharmacyMedicinal ChemistryPharmacologyDrug DesignDrug DiscoveryStructure-activity RelationshipsEnzyme InhibitionHit-to-lead OptimizationLead Compound DesignLead DiscoveryPotency OptimizationJnk Pathway ActivationKinase Inhibitor Library DesignKinase InhibitorsKinase Selectivity ProfilingLead Compound OptimizationLead Compound ScreeningLead ScaffoldsSelectivity
3-alkyl-5-aryl-1-pyrimidyl-1H-pyrazole derivatives were designed and synthesised as selective inhibitors of JNK3, a target for the treatment of neurodegenerative diseases. Following previous studies, we have designed JNK3 inhibitors to reduce the molecular weight and successfully identified a lead compound that exhibits equipotent activity towards JNK3. Kinase profiling results also showed high selectivity for JNK3 among 38 kinases. Among the derivatives, the IC50 value of 8a, (R)-2-(1-(2-((1-(cyclopropanecarbonyl)pyrrolidin-3-yl)amino)pyrimidin-4-yl)-5-(3,4-dichlorophenyl)-1H-pyrazol-3-yl)acetonitrile exhibited 227 nM, showing the highest inhibitory activity against JNK3.
12
The stress-activated protein kinase subfamily of c-Jun kinases
John Kyriakis, Papia T. Banerjee, Eleni Nikolakaki et al. · Nature · 1994 · 2.6K citations
Selective interaction of JNK protein kinase isoforms with transcription factors.
Shreyasi Gupta, Tyler W. Barrett, Alan J. Whitmarsh et al. · The EMBO Journal · 1996 · 1.3K citations · Full text
The JNK signal transduction pathway
Claire R. Weston · Current Opinion in Cell Biology · 2007 · 1K citations